Myelofibrosis (MF) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051126
Expand allThis document outlines details of PBS-subsidised momelotinib and ruxolitinib for patients with MF. As of 1 April 2025, this program has moved to the general schedule.
For details on how to process a PBS Authority, see Process telephone Authority approval application.
Myelofibrosis quick reference
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
|
Initial |
Telephone Electronic S85: momelotinib ruxolitnib |
No |
OPA |
Not specified |
Yes |
|
Continuing |
Streamlined S85: momelotinib ruxolitnib |
No |
N/A |
Not specified |
N/A |